We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Technique Detects Biomarkers for Kidney Diseases with Nephritic Syndrome

By LabMedica International staff writers
Posted on 27 May 2024
Print article
Image: Researchers have detected novel biomarkers for kidney diseases using a new technique (Photo courtesy of 123RF)
Image: Researchers have detected novel biomarkers for kidney diseases using a new technique (Photo courtesy of 123RF)

Nephrotic syndrome is associated with several kidney diseases such as minimal change disease (MCD), primary focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN), and is characterized by high levels of protein in the urine. This condition primarily stems from damage to podocytes, the cells that filter blood in the kidneys, which results in protein leakage into the urine. Often, children diagnosed with MCD or FSGS are categorized under idiopathic nephrotic syndrome (INS), indicating an unknown cause. This is typically because children with elevated urinary protein levels seldom undergo kidney biopsies, which are the standard method for determining the underlying cause. Traditionally, the diagnosis of these conditions has been complicated due to their similar histological features and a general reluctance to perform invasive kidney biopsies, especially in children. Although anti-nephrin autoantibodies have been detected in some patients with MCD and FSGS, their exact role in the progression of these diseases remains unclear. A groundbreaking study recently presented at the 61st ERA Congress has made a significant breakthrough in diagnosing and monitoring kidney diseases linked to nephrotic syndrome.

Researchers at the University Medical Center Hamburg-Eppendorf (Hamburg, Germany) utilized a hybrid method to identify anti-nephrin autoantibodies as a reliable biomarker for tracking the progression of these diseases, paving the way for tailored treatment strategies. The study, which spanned across Europe and the USA, employed a novel combination of immunoprecipitation and enzyme-linked immunosorbent assay (ELISA) to accurately detect anti-nephrin autoantibodies. The results showed that these autoantibodies were present in 69% of adults with MCD and 90% of children with INS who had not received immunosuppressive treatments. The levels of these antibodies also correlated with the activity of the disease, indicating their potential as a biomarker for monitoring disease progression. These antibodies were seldom found in other diseases being studied.

In further experiments, researchers introduced laboratory-synthesized nephrin protein to mice, simulating conditions similar to MCD. This immunization led to phosphorylation of nephrin and significant changes in cellular structures, suggesting that antibodies targeting nephrin play a role in podocyte dysfunction and the onset of nephrotic syndrome. Remarkably, this model required only a single immunization to trigger rapid disease onset, even with low concentrations of antibodies, unlike other models that need multiple immunizations.

“The identification of anti-nephrin autoantibodies as a reliable biomarker, coupled with our hybrid immunoprecipitation technique, enhances our diagnostic capabilities and opens new avenues for closely monitoring disease progression in kidney disorders with nephrotic syndrome,” said Dr. Nicola M. Tomas, co-lead author of the study.

“By providing insights into underlying mechanisms, these findings lay the groundwork for personalized interventions and pave the way for a new era of precision medicine for these complex conditions," added Professor Tobias B. Huber, lead author of the study.

Related Links:
University Medical Center Hamburg-Eppendorf

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Hematology Analyzer
XS-500i
New
Myocardial Infarction Test
Savvycheck SensA Heart

Print article

Channels

Microbiology

view channel
Image: The breakthrough system offers a faster way to diagnose bloodborne infections (Photo courtesy of Melio)

Culture-Free Platform Rapidly Identifies Blood Stream Infections

Neonatal sepsis is a life-threatening condition that results from bloodstream infections in newborns under 28 days old. Due to their immature immune systems, newborns are especially vulnerable to infections.... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.